Anti-SARS-CoV-2 antibody response after 2 and 3 doses of BNT162b2 mRNA vaccine in patients with lymphoid malignancies

被引：13

作者：

Gressens, Simon B. ^{[1
]}

Fourati, Slim ^{[2
]}

Le Bouter, Anne ^{[2
]}

Le Bras, Fabien ^{[3
]}

Dupuis, Jehan ^{[3
]}

Hammoud, Mohammad ^{[3
]}

El Gnaoui, Taoufik ^{[3
]}

Gounot, Romain ^{[3
]}

Roulin, Louise ^{[3
]}

Belhadj, Karim ^{[3
]}

Haioun, Corinne ^{[3
]}

Gallien, Sebastien ^{[1
,4
]}

Melica, Giovanna ^{[1
,4
]}

Lemonnier, Francois ^{[3
,4
]}

机构：

[1] Univ Paris Est Creteil, Hop Univ Henri Mondor, AP HP, Infect Dis & Immunol Dept, Creteil, France

[2] Univ Paris Est, Hop Henri Mondor, AP HP, Virol Unit,Dept Prevent Diag & Treatment Infect, Creteil, France

[3] Grp Hosp Univ Chenevier Mondor, AP HP, Serv Unite Hemopathies Lymphoides, Creteil, France

[4] Univ Paris Est Creteil, IMRB, INSERM, Creteil, France

来源：

CLINICAL MICROBIOLOGY AND INFECTION | 2022年 / 28卷 / 06期

关键词：

COVID-19; Haematologicalmalignancies; Immunocompromised; Third dose; Vaccine;

D O I：

10.1016/j.cmi.2022.02.029

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Objectives: COVID-19 patients affected by haematological malignancies have a more severe course of the disease and higher mortality, prompting for effective prophylaxis. The present study aims to evaluate the humoral response after mRNA vaccination as well as the impact of a third vaccine dose in patients with lymphoid malignancies. Methods: We conducted a single-centre study, evaluating the serological responses of mRNA vaccination amongst a cohort of 200 patients affected by lymphoid malignancies after two or three doses using an industrial SARS-CoV-2 serology assay for anti-receptor binding domain (RBD) Spike IgG detection and quantification. Results: Among patients with plasma cell disorders, 59 of 96 (61%) had seroconversion (anti-RBD >50 AU/mL), and recent anti-CD38 therapies were associated with lower serological anti-RBD IgG concentrations (median IgG concentration 137 (IQR 0-512) AU/mL vs. 543 (IQR 35-3496) AU/mL; p < 0.001). Patients with B-cell malignancies had a lower seroconversion rate (20/84, 24%) mainly due to the broad usage of anti-CD20 monoclonal antibodies; only 2 of 53 (4%) patients treated by anti-CD20 antibodies during the last 12 months experienced a seroconversion. A total of 78 patients (44 with plasma cell disorders, 27 with B-cell malignancies, and 7 with other lymphomas) received a third dose of vaccine. The seroconversion rate and antibody concentrations increased significantly, especially in patients with plasma cell disorders, where an increment of anti-RBD IgG concentrations was observed in 31 of 44 (70%) patients, with an anti-RBD concentration median-fold increase of 10.6 (IQR 2.4-25.5). Its benefit in B-cell malignancies is uncertain, with only 2 of 25 (8%) patients having seroconverted after the vaccine booster, without increased median antibody concentration. Discussion: A third mRNA vaccine dose significantly improved humoral responses among patients with plasma cell disorders, whereas the effect was limited among patients with B-cell malignancies. (C) 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

引用

页码：885.e7 / 885.e11

页数：5

共 15 条

[1]

[Anonymous], FRANCE RECOMMANDATIO

[2] CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer [J].

Bange, Erin M. ;

Han, Nicholas A. ;

Wileyto, Paul ;

Kim, Justin Y. ;

Gouma, Sigrid ;

Robinson, James ;

Greenplate, Allison R. ;

Hwee, Madeline A. ;

Porterfield, Florence ;

Owoyemi, Olutosin ;

Naik, Karan ;

Zheng, Cathy ;

Galantino, Michael ;

Weisman, Ariel R. ;

Ittner, Caroline A. G. ;

Kugler, Emily M. ;

Baxter, Amy E. ;

Oniyide, Olutwatosin ;

Agyekum, Roseline S. ;

Dunn, Thomas G. ;

Jones, Tiffanie K. ;

Giannini, Heather M. ;

Weirick, Madison E. ;

McAllister, Christopher M. ;

Babady, N. Esther ;

Kumar, Anita ;

Widman, Adam J. ;

DeWolf, Susan ;

Boutemine, Sawsan R. ;

Roberts, Charlotte ;

Budzik, Krista R. ;

Tollett, Susan ;

Wright, Carla ;

Perloff, Tara ;

Sun, Lova ;

Mathew, Divij ;

Giles, Josephine R. ;

Oldridge, Derek A. ;

Wu, Jennifer E. ;

Alanio, Cecile ;

Adamski, Sharon ;

Garfall, Alfred L. ;

Vella, Laura A. ;

Kerr, Samuel J. ;

Cohen, Justine, V ;

Oyer, Randall A. ;

Massa, Ryan ;

Maillard, Ivan P. ;

Maxwell, Kara N. ;

Reilly, John P. .

NATURE MEDICINE, 2021, 27 (07) :1280-+

[3] Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab [J].

Cattaneo, C. ;

Cancelli, V ;

Imberti, L. ;

Dobbs, K. ;

Sottini, A. ;

Pagani, C. ;

Belotti, A. ;

Re, A. ;

Anastasia, A. ;

Quaresima, V ;

Tucci, A. ;

Chiorini, J. A. ;

Su, H. C. ;

Cohen, J., I ;

Burbelo, P. D. ;

Rossi, G. ;

Notarangelo, L. D. .

BLOOD CANCER JOURNAL, 2021, 11 (09)

[4] Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy [J].

Dulery, Remy ;

Lamure, Sylvain ;

Delord, Marc ;

Di Blasi, Roberta ;

Chauchet, Adrien ;

Hueso, Thomas ;

Rossi, Cedric ;

Drenou, Bernard ;

Deau Fischer, Benedicte ;

Soussain, Carole ;

Feugier, Pierre ;

Noel, Nicolas ;

Choquet, Sylvain ;

Bologna, Serge ;

Joly, Bertrand ;

Philippe, Laure ;

Kohn, Milena ;

Malak, Sandra ;

Fouquet, Guillemette ;

Daguindau, Etienne ;

Taoufik, Yassine ;

Lacombe, Karine ;

Cartron, Guillaume ;

Thieblemont, Catherine ;

Besson, Caroline .

AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (08) :934-944

[5] Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2 [J].

Ebinger, Joseph E. ;

Fert-Bober, Justyna ;

Printsev, Ignat ;

Wu, Min ;

Sun, Nancy ;

Prostko, John C. ;

Frias, Edwin C. ;

Stewart, James L. ;

Van Eyk, Jennifer E. ;

Braun, Jonathan G. ;

Cheng, Susan ;

Sobhani, Kimia .

NATURE MEDICINE, 2021, 27 (06) :981-+

[6] Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab [J].

Felten, Renaud ;

Gallais, Floriane ;

Schleiss, Cedric ;

Chatelus, Emmanuel ;

Javier, Rose-Marie ;

Pijnenburg, Luc ;

Sordet, Christelle ;

Sibilia, Jean ;

Arnaud, Laurent ;

Fafi-Kremer, Samira ;

Gottenberg, Jacques-Eric .

LANCET RHEUMATOLOGY, 2022, 4 (01) :E13-E16

[7] Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+B-Lymphocyte Count and Anti-CD38 Treatment [J].

Ghandili, Susanne ;

Schonlein, Martin ;

Lutgehetmann, Marc ;

zur Wiesch, Julian Schulze ;

Becher, Heiko ;

Bokemeyer, Carsten ;

Sinn, Marianne ;

Weisel, Katja C. ;

Leypoldt, Lisa B. .

CANCERS, 2021, 13 (15)

[8] Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies [J].

Greenberger, Lee ;

Saltzman, Larry ;

Senefeld, Jonathon ;

Johnson, Patrick ;

DeGennaro, Louis ;

Nichols, Gwen .

CANCER CELL, 2021, 39 (10) :1297-1299

[9] Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients [J].

Kamar, Nassim ;

Abravanel, Florence ;

Marion, Olivier ;

Couat, Chloe ;

Izopet, Jacques ;

Del Bello, Arnaud .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (07) :661-662

[10]

Monin-Aldama L, 2021, MEDRXIV

← 1 2 →